Complex pharmacokinetics of a humanized antibody against human amyloid beta peptide, anti-abeta Ab2, in nonclinical species.
about
Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development.Predicting pharmacokinetic profile of therapeutic antibodies after iv injection from only the data after sc injection in cynomolgus monkey.Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges.Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration.ADME of biologics-what have we learned from small molecules?Balancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokineticsFramework selection can influence pharmacokinetics of a humanized therapeutic antibody through differences in molecule charge.Challenges and opportunities in absorption, distribution, metabolism, and excretion studies of therapeutic biologics.Evaluating the Use of Antibody Variable Region (Fv) Charge as a Risk Assessment Tool for Predicting Typical Cynomolgus Monkey PharmacokineticsAberrant bispecific antibody pharmacokinetics linked to liver sinusoidal endothelium clearance mechanism in cynomolgus monkeysMonoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development?Pharmacokinetic and pharmacodynamic considerations for the next generation protein therapeutics.Challenges and opportunities for the future of monoclonal antibody development: Improving safety assessment and reducing animal use.Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins.Pharmacokinetic de-risking tools for selection of monoclonal antibody lead candidates.Engineering the surface properties of a human monoclonal antibody prevents self-association and rapid clearance in vivo.A strategy for risk mitigation of antibodies with fast clearance.Identification of polymorphisms in genes of the immune system in cynomolgus macaques.Anti-neuropilin-1 (MNRP1685A): unexpected pharmacokinetic differences across species, from preclinical models to humans.Application of human FcRn transgenic mice as a pharmacokinetic screening tool of monoclonal antibody.
P2860
Q30930928-DFF8C72E-7D5E-443D-A6FD-1F40522A81E0Q31091923-73CE1A73-56DD-4C16-A5F0-FFC2D760B55AQ35929084-5F4897A9-9853-4B96-8A6C-4199158FF911Q35992509-B9ADE38C-93B7-4D90-B668-0019B50FA356Q36065589-98F546AA-4227-44DE-AE85-106A2ACC313EQ36214515-8F8D07C7-D7CD-4B5D-BB64-D9D77997BDBDQ36215733-916D8961-18A9-4D31-8563-7444A9D24520Q36331497-C775FFED-9E71-4246-A22E-039D46674003Q36444225-4CDC19F1-53E3-4B6C-B3CB-F7E4121169C8Q37141605-40EB84A0-EB60-48C0-82E6-DEA57D39D59CQ37976121-72FCB1A3-1CAA-4AE6-A1BE-CCF0D95E6B0CQ38587550-EBD99EC5-1B1D-4653-A7B9-16CB193B5234Q38687397-BA2B6D8D-EED4-4C12-AFAD-55A94799572FQ38831148-8439EC2C-1985-48C1-BB03-8B200C4A0E10Q39277950-1D91AE25-274F-4729-9C8F-9AFAECEF2E39Q39496098-3D13AAE1-2517-4B8B-8604-A8F331010908Q41575498-4A2E535F-4440-4A24-98E1-3BEC43181388Q45029012-9DF8621B-47B2-4BA5-810F-70AD3943FF56Q46211189-52C957F8-E191-46C1-9217-297047C17397Q46866013-6A629D90-BA26-45FC-9C19-C14AA1CB97DF
P2860
Complex pharmacokinetics of a humanized antibody against human amyloid beta peptide, anti-abeta Ab2, in nonclinical species.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Complex pharmacokinetics of a ...... a Ab2, in nonclinical species.
@en
Complex pharmacokinetics of a ...... a Ab2, in nonclinical species.
@nl
type
label
Complex pharmacokinetics of a ...... a Ab2, in nonclinical species.
@en
Complex pharmacokinetics of a ...... a Ab2, in nonclinical species.
@nl
prefLabel
Complex pharmacokinetics of a ...... a Ab2, in nonclinical species.
@en
Complex pharmacokinetics of a ...... a Ab2, in nonclinical species.
@nl
P2093
P2860
P1476
Complex pharmacokinetics of a ...... a Ab2, in nonclinical species.
@en
P2093
David Wensel
Davinder Gill
Garvin Warner
Lioudmila Tchistiakov
Michel Awwad
Pam Szklut
Yulia Vugmeyster
P2860
P304
P356
10.1007/S11095-011-0405-X
P577
2011-03-18T00:00:00Z